Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Nanocarrier-based Strategies: Advancing the Future of Pulmonary Drug Delivery

Title: Nanocarrier-based Strategies: Advancing the Future of Pulmonary Drug Delivery
Authors: Yadav, Prem; Jaiswal, Sandhya; Yadav, Kiran; Mitra, Reema; Ahirrao, Pallavi
Source: Current Respiratory Medicine Reviews ; volume 22 ; ISSN 1573-398X
Publisher Information: Bentham Science Publishers Ltd.
Publication Year: 2026
Description: Pulmonary diseases such as lung cancer, cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) are chronic conditions that remain significant global health burdens due to their high prevalence and suboptimal treatment outcomes. Conventional systemic therapies often result in limited drug accumulation at the site of disease and increased risk of systemic side effects. Site-specific mucosal drug delivery to the lungs has emerged as a promising strategy to enhance therapeutic efficacy by ensuring localized drug action and reducing systemic exposure. However, the complex anatomical and physiological barriers of the respiratory tract, i.e., the mucus layer, mucociliary clearance, epithelial tight junctions, and immune defences, pose significant challenges to effective drug delivery and absorption. The study aims to investigate site-specific mucosal drug delivery systems for pulmonary diseases, focusing on nanocarrier-based strategies. It explores physiological and biological barriers in the respiratory tract, recent advances in liposomes, polymeric and solid lipid nanoparticles, functionalization approaches, and integration with inhalation technologies to enhance targeting, bioavailability, and therapeutic outcomes. A comprehensive review of published literature retrieved from scientific databases such as Elsevier, PubMed, and Google Scholar. Relevant preclinical and clinical studies focusing on nanotechnology-based mucosal drug delivery for pulmonary diseases were selected. Emphasis was placed on articles discussing nanocarrier design, targeting strategies, bioavailability, and therapeutic outcomes. Nanocarriers demonstrate significant potential in enhancing mucosal drug delivery through improved adherence, penetration, and controlled release. Functionalization with disease-specific ligands or stimuli-responsive elements further increases their therapeutic precision. Liposomes and polymeric nanoparticles, in particular, show high biocompatibility and tunability. Despite promising ...
Document Type: article in journal/newspaper
Language: English
DOI: 10.2174/011573398x444443260129095501
DOI: 10.2174/011573398X444443260129095501
Availability: https://doi.org/10.2174/011573398x444443260129095501; https://www.eurekaselect.com/article/download?doi=10.2174/011573398X444443260129095501; https://www.eurekaselect.com/251479/article
Accession Number: edsbas.1CB8B56F
Database: BASE